Drug Profile
Research programme: diagnostic and imaging agents - GE Healthcare/Pieris Pharmaceuticals
Alternative Names: Anticalins - GE Healthcare/Pieris Pharmaceuticals; Lipocalin derivatives - GE Healthcare/Pieris PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GE Healthcare; Pieris
- Developer GE Healthcare; Pieris Pharmaceuticals
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined(Diagnosis) in Germany
- 27 Oct 2006 Early research in Diagnostic imaging in Germany (unspecified route)